Moreover, exogenous treatment with CoA to CD8+T cells reprograms them to Tc22s by increasing their OXPHOS, which upregulates hypoxia-inducible factor-1a (HIF-1a) and Ahr activity and increases the antitumor action of Tc22s (IL-22 and IL-2 release) in murine cancer models and patients with melanoma receiving anti-PD-L1 ICIs [264]. The gene discussed is CD8A; the disease is cancer.